Invivyd Inc (IVVD)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$0.83-1.08%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
Intact: The reason to own it still holds.
Invivyd is growing PEMGARDA revenue, which rose 22% to $13.7 million in Q1 2026. The company aims to increase this revenue further. Despite losses, management is focused on growth. The recent selloff makes valuation attractive.
The company is still loss-making and EPS estimates are negative through 2027. Revenue growth is modest and uncertain. The recent 47% drawdown shows investor skepticism. Debt issuances and earnings misses add risk.
The market expects about 37% revenue growth next year but prices in continued losses and high risk. Our fair value near $2.5 reflects this cautious outlook. The stock is down 47% from highs, signaling stress.
Breaks if: Total revenue falls below $13 million in FY 2025
Continue to grow PEMGARDA net product revenue despite diminished COVID vaccine utilization.
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and faces high risks, but it operates in a sector with favorable tailwinds that could support future growth.
The market appears to have priced in a low expectations gap, suggesting that IVVD is seen as relatively cheap compared to its peers. However, the low model confidence indicates uncertainty about future performance.
Recent financial performance has been weak, with a notable drop in company momentum. Management has prioritized revenue growth from PEMGARDA and advancing clinical trials, but results have been mixed.
Key factors for the future include the company's ability to maintain revenue growth and successfully advance clinical programs. Additionally, guidance changes and broader economic conditions, such as job market performance, could significantly impact sentiment.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The company missed earnings by $0.03. Revenue also fell short of estimates. This indicates potential revenue growth issues for IVVD. There are no new supports to strengthen the read.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Stated as a priority in 2 of last 2 quarters. PEMGARDA net product revenue grew from $11.8 million in 2025-Q2 to $14.3 million in 2026-Q2, a 21% increase year-over-year, and from $11.3 million in 2025-Q1 to $13.7 million in 2026-Q1, a 22% increase. Management has consistently emphasized continued growth despite diminished COVID vaccine utilization, and the trajectory is delivering.
“Achieved Q2 2026 PEMGARDA net product revenue of $14.3 million, representing 21% growth versus Q2 2025”
“Achieved Q1 2026 PEMGARDA net product revenue of $13.7 million, representing 22% growth versus Q1 2025”
Breaks if: PEMGARDA revenue falls below $11 million next year
Continue to grow PEMGARDA net product revenue despite diminished COVID vaccine utilization.
Stated as a priority in 2 of last 2 quarters. PEMGARDA net product revenue grew from $11.8 million in 2025-Q2 to $14.3 million in 2026-Q2, a 21% increase year-over-year, and from $11.3 million in 2025-Q1 to $13.7 million in 2026-Q1, a 22% increase. Management has consistently emphasized continued growth despite diminished COVID vaccine utilization, and the trajectory is delivering.
“Achieved Q2 2026 PEMGARDA net product revenue of $14.3 million, representing 21% growth versus Q2 2025”
“Achieved Q1 2026 PEMGARDA net product revenue of $13.7 million, representing 22% growth versus Q1 2025”
Breaks if: EPS loss worsens beyond -$0.53 in FY 2026
Over the next 1 to 3 years, IVVD's performance will depend on its execution of strategic priorities and external economic factors. Not investment advice.